Affinity between the PCR and antigen tests and their positivity for Covid-19 in Colombia

Afinidad entre las pruebas PCR y Antígeno, y su positivad para COVID-19 en Colombia

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) has spread rapidly around the world since it emerged in Wuhan, China, in late 2019. Objective: to describe the positivity rates of samples tested for SARS-CoV-2. Methodology: the research focused on PCR and antigen tests processed for COVID-19, using the information released by the National Institute of Health between January 1 and March 31 2021. Results: the highest positivity rate for PCR testing for each month between January to March 2021 in Colombia was found on the following days: January 12: 56.3%, January 7: 44.9%, January 6: 45.1%, January 5: 43.7%, January 2: 38.1%, March 24: 35.2% and March 26: (31.3%. The days with the highest percentage of positive cases found by antigen testing for each month from January to March 2021 in Colombia, were January 11: 32.7%, January 4: 31.0%, January 15: 28.9%, January 18: 22.4%, March 22: 21.1%, March 28: 20.7%  and February 17: 20.1%. Conclusion: an active search of infected people must be continued through the practice of a greater number of PCR and viral antigen and molecular tests. The latter has been reported by the EPS to show very high accuracy, which accelerates the result delivery process.

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi: 10.1056/NEJMoa2001316
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu, Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3
3. Hoffmann, M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052
4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. doi: 10.1001/jama.2020.5394
5. Docherty A, Harrison E, Verde C, Hardwick S, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985
6. Richardson S, Hirsch J, Narasimhan S, Crawford J, McGinn T, Davidson K, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775
7. Petrilli C, Jones S, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin K, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966
8. Lewnard J, Liu V, Jackson M, Schmidt M, Jewell B, Flores J, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020;369:m1923. doi: 10.1136/bmj.m1923
9. Wu A, Wang L, Yang Z, Ji S, Xa S, Cao Y, Jing Meng J, Ding X, Gold S, Jiang T, Cheng G. One year of SARS-CoV-2 evolution. Cell Host Microbe. 2021 Apr 14;29(4):503-507. doi: 10.1016/j.chom.2021.02.017
10. Díaz-Pinzón JE. Uso de modelo predictivo para la dinámica de transmisión del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):34-44. doi: 10.31260/RepertMedCir.01217372.1056
11. National Center for Immunization, Respiratory Diseases (NCIRD), Division of Viral Diseases. Interim Guidance for Antigen Testing for SARS-CoV-2 [Internet]. United State: Centers for Diseases Control and Prevention; 2020 [cited 2021 marzo 19]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html.
12. Ministerio de Salud y Protección Social. Lineamientos para el uso de pruebas en el laboratorio de salud pública (lSP) en el marco de la emergencia sanitaria por (covid-19) en Colombia. Colombia: Ministerio de Salud y Protección Social; 2020. p. 29.
13. Ministerio de Salud y Protección Social. Lineamientos para el uso de pruebas moleculares RT-PCR, pruebas de antígeno y pruebas serológicas para SARS-CoV-2 (COVID-19) en Colombia. Colombia: Ministerio de Salud y Protección Social; 2020. p.34.
14. Díaz Pinzón JE. Soporte técnico de simulación Phet en la enseñanza y aprendizaje de fracciones equivalentes. Rev Invest Univ Quindío (Col.). 2016;28(2):31-41
15. Díaz-Pinzón JE. Correlación y regresión lineal de la evaluación tiempo y puntaje con recurso interactivo flash. INNOVA Research Journal. 2017;2(10):1-8. doi: 10.33890/innova.v2.n10.2017
16. Díaz-Pinzón JE. Estudio de los resultados del contagio por COVID-19 a nivel mundial. Repert Med Cir. 2020;29(Núm.Supl.1):65-71. doi: 10.31260/RepertMedCir.01217372.1089
17. Instituto Nacional de Salud. Coronavirus (COVID-2019) en Colombia [Internet]. Bogotá: Instituto Nacional de Salud; 2020 [citado 2021 marzo 19]; Recuperado de: https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx
18. Díaz-Pinzón JE. Positividad y proporción para muestras por COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):127-130. doi: 10.31260/RepertMedCir.01217372.1134